Cleveland Clinic Study Will Measure NSAID Safety In Heart Disease Patients
This article was originally published in The Tan Sheet
The cardiovascular safety of ibuprofen, naproxen and celecoxib (Pfizer's Celebrex) will be compared in a worldwide clinical trial involving 20,000 patients, the Cleveland Clinic announced Dec. 13
You may also be interested in...
Naproxen should be excluded from any cardiovascular warnings required for NSAIDs, FDA's joint panel on COX-2 safety recommended Feb. 18
A new website from Pfizer touting the firm's COX-2 pain reliever Celebrex (celecoxib) questions the perceived safety profile of over-the-counter drugs
FDA should issue a public health alert to warn consumers about potential health risks that may result from use of Herbalife dietary supplements and should remove the company's products from the market, pending further investigation of lead contamination, according to Christopher Grell, an attorney whose firm specializes in ephedra and dietary supplement litigation